{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:58:02Z","timestamp":1787014682699,"version":"build-2736575974"},"reference-count":27,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2009,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To analyse the durability of response for patients with non\u2010muscle\u2010invasive bladder cancer (NMIBC) refractory to bacille Calmette\u2010Gu\u00e9rin (BCG) therapy and treated with intravesical docetaxel in a combined induction and maintenance regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>A previous phase I trial showed docetaxel to be safe for intravesical therapy, with no systemic absorption and minimal toxicity after six weekly instillations for patients with BCG\u2010refractory NMIBC. In that trial, docetaxel gave a 56% complete response (CR) rate at 12\u2003weeks, but the durability was only 22%. Thus a second group of patients was treated with a 6\u2010week induction and then given monthly maintenance therapy with intravesical docetaxel. Thirteen patients with BCG\u2010refractory Ta, T1, or Tis transitional cell carcinoma were treated. Induction therapy was administered as six weekly intravesical instillations of 75\u2003mg followed by single\u2010dose monthly maintenance therapy for nine additional instillations in patients who had a CR. The initial response at 12\u2003weeks from the start of induction therapy was evaluated by cystoscopy with biopsy, and urine cytology. The follow\u2010up consisted of quarterly cystoscopy with biopsy and cytology, and periodic imaging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>The median follow\u2010up was 13\u2003months; 10 of 13 patients had a CR after induction, and six have remained disease\u2010free during the follow\u2010up. Of those in who the treatment failed, six had transurethral resection of the tumour and one a cystectomy. All 10 initial responders completed at least three instillations of maintenance therapy to date (median nine instillations), of whom six have remained recurrence\u2010free.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Monthly maintenance therapy with intravesical docetaxel appears to extend the durability of response to induction treatment for a selected group of patients with BCG\u2010refractory NMIBC, and might decrease the overall risk of recurrence in high\u2010risk NMIBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2009.08543.x","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T06:45:21Z","timestamp":1239777921000},"page":"1098-1102","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A single\u2010institution experience with induction and maintenance intravesical docetaxel in the management of non\u2010muscle\u2010invasive bladder cancer refractory to bacille Calmette\u2010Gu\u00e9rin therapy"],"prefix":"10.1111","volume":"104","author":[{"given":"LaMont","family":"Barlow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"McKiernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihor","family":"Sawczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,9,14]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/CA.2007.0010"},{"key":"e_1_2_8_3_2","first-page":"2785","volume-title":"Campbell\u2019s Urology","author":"Malkowicz SB","year":"2002"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.15.3185"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)49690-X"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67707-5"},{"key":"e_1_2_8_7_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette\u2010Guerin therapy for superficial bladder cancer: a 10\u2010year followup","volume":"147","author":"Herr HW","year":"1992","journal-title":"J Urol"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)66692-8"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200118050-00004"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.063"},{"key":"e_1_2_8_11_2","doi-asserted-by":"crossref","unstructured":"LammDL O\u2019DonnellMA Genitourinary Oncology Study Group.Multicenter randomized comparison of BCG with or without alfa 2b interferon (IFN) and Oncovite (ONC) versus recommended daily allowance (RDA) vitamins during induction and extended 3\u2010week maintenance.AUA Annual Meeting 2008","DOI":"10.1016\/S0022-5347(08)61713-9"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.681"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2341"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.1161"},{"key":"e_1_2_8_16_2","unstructured":"LaudanoMA MurphyAM PetrylakDP DesaiM BensonMC McKiernanJM.Long term clinical outcome of a phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy.AUA Annual Meeting;2008May 18"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)51695-X"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)56073-5"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)43959-0"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)32741-6"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)52736-6"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)39546-0"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67608-0"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41291-2"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)62068-8"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)41801-5"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)65570-8"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(93)90329-9"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2009.08543.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2009.08543.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:25:37Z","timestamp":1761755137000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2009.08543.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,14]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1464-410X.2009.08543.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2009.08543.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,14]]},"assertion":[{"value":"2009-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}